Lucid files for 1-for-10 reverse stock split requiring shareholder approval
RAMSEY, N.J. - ADMA Biologics, Inc. (NASDAQ:ADMA) shares jumped 4.55% after the biopharmaceutical company reported fourth quarter earnings and revenue that beat analyst estimates, while also raising its future guidance.
The company posted Q4 adjusted earnings per share of $0.46, surpassing the $0.15 consensus estimate by $0.31. Revenue came in at $117.5 million, topping expectations of $113.4 million.
For the full year 2024, ADMA reported total revenue of $426.5 million, up 65% YoY. Adjusted EBITDA increased 309% to $164.6 million.
"ADMA delivered exceptional operating and financial results in 2024, with total revenues and Adjusted EBITDA growing 65% and 309% year-over-year, respectively," said Adam Grossman, President and CEO.
The company raised its guidance, now expecting FY2025 revenue of over $490 million and FY2026 revenue exceeding $605 million. ADMA also anticipates generating over $1 billion in annual revenue prior to 2030.
ADMA cited recently secured long-term high-titer plasma supply agreements as a key driver for future growth, particularly for its ASCENIV product. The company expects these agreements to significantly expand plasma sourcing capacity and de-risk both near-term and long-term growth trajectories.
At the end of 2024, ADMA reported over $103 million in total cash, including $60 million of debt organically discharged during the second half of the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.